🔎 Trials Near Me

Utama › Kanser Paru-paru Bukan Sel Kecil › Oklahoma › Oklahoma City

Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Oklahoma City, OK

28 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Oklahoma City (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Mengambil pesertaFasa 3
  • University of Oklahoma Health Sciences Center, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT07388524

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Mengambil pesertaFasa 3
  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Mercy Hospital Oklahoma City, Oklahoma City
  • Integris Cancer Institute of Oklahoma, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT04267848

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Mengambil pesertaFasa 1/2
  • University of Oklahoma, Oklahoma City
Umur 12 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04585750

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Mengambil pesertaFasa 3
  • University of Oklahoma Health Sciences Center, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06498635

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Mengambil pesertaFasa 3
  • Local Institution - 0418, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07361510

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Mengambil pesertaFasa 2
  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Mercy Hospital Oklahoma City, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT03191149

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Mengambil pesertaFasa 2/3
  • INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06712316

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Mengambil pesertaFasa 1/2
  • University of Oklahoma, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06128551

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Mengambil pesertaFasa 3
  • Clinical Study Site, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06767514

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Mengambil pesertaFasa 1/2
  • OU Health Stephenson Cancer Center, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06303505

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Mengambil pesertaFasa 1
  • OU Health Stephenson Cancer Center, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06253871

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Mengambil pesertaFasa 3
  • University of Oklahoma Health Sciences Center, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06500481

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Mengambil pesertaFasa 1/2
  • University of Oklahoma - Health Sciences Center, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT05579366

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Mengambil pesertaFasa 3
  • University of Oklahoma Health Sciences Center, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Jul 2026 · NCT06686771

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Mengambil pesertaFasa 1
  • OU Health University of Oklahoma Medical Center, Oklahoma City
  • Stephenson Cancer Center (chemo location), Oklahoma City
  • University of Oklahoma Health Science Center, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Jul 2026 · NCT04389632

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

Mengambil pesertaKajian pemerhatian
  • Mercy Hospital - OKC, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT07327489

Study of XB010 in Subjects With Solid Tumors

Mengambil pesertaFasa 1
  • Stephenson Cancer Center, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jun 2026 · NCT06545331

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Mengambil pesertaFasa 1
  • OU Stephenson Cancer Center, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jun 2026 · NCT06026410

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2
  • University of Oklahoma Health Sciences Center, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Jun 2026 · NCT05642572

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Mengambil pesertaFasa 1/2
  • Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Mei 2026 · NCT05431270

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2
  • University of Oklahoma Health Sciences Center, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2/3
  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Integris Southwest Medical Center, Oklahoma City
  • Mercy Hospital Oklahoma City, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Mei 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2
  • University of Oklahoma Health Sciences Center, Oklahoma City
18 Minutes · Semua jantina · Dikemas kini 5 Mei 2026 · NCT06031688

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Mengambil pesertaKajian pemerhatian
  • Mercy Hospital Oklahoma City, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204

GEMINI-NSCLC: NSCLC Biomarker Study

Mengambil pesertaKajian pemerhatian
  • Hightower Clinical, Oklahoma City
  • Mercy Clinic Oncology and Hematology - Coletta, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Feb 2026 · NCT05236114

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Mengambil pesertaFasa 1
  • Dren Investigational Site, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jan 2026 · NCT06999187

A Study of NX-1607 in Adults With Advanced Malignancies

Mengambil pesertaFasa 1
  • University of Oklahoma, Oklahoma City
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2025 · NCT05107674

Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain

Kajian lain di Oklahoma City

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.